Precision Microbiome Therapeutics
Identifing drugs that target the gut microbiome Modulating the production of specific metabolites by the gut microbiome to improve human health.
MedBiome Inc. was launched in 2018 as the result of technologies developed at the University of Ottawa.
MedBiome focuses on the development of Precision Microbiome Therapeutics that target the production of specific metabolites by the human microbiome. MedBiome’s core technology, called RapidAIM, allows the rapid screening of compounds against individual human microbiomes. RapidAIM provides unprecedented insight into the metabolism of the microbiome. This insight accelerates the discovery of compounds that target the production of specific metabolites by the human microbiome. RapidAIM can also be used to:
- de-risk compounds.
- stratify patients based on their microbiome responses.
- understand how drugs affect the microbiome.
- understand how the microbiome affects drugs.
- other applications.
Using RapidAIM, MedBiome is focused on discovery and development of Precision Microbiome Therapeutics that target the human microbiome to modulate the production of specific metabolites, metabolic pathways and enzymes.
MedBiome is developing compounds that target the human microbiome for four disease areas all with significant unmet medical needs. These include:
- Inflammatory Bowel Disease for Pediatrics (IBD).
- Early stage Alzheimer’s Disease (AD).
- Chronic Kidney Disease (CKD).
- Colorectal Cancer (CRC).
- focuses on screening compounds against individual microbiomes.
- develops compound libraries that can reach the gut microbiome.
- provides industry leading functional metaproteomics, metagenomics and metabolomics approaches.
- provides leading bioinformatics and software tools to assess the effects of drugs on the microbiome.
Our mission is to improve human health through the microbiome.
There is a strong relationship between the human gut microbiota and human health. The human gut microbiome produces metabolites involved in health and diseases. Understanding how drugs impact the production of metabolites by the gut microbiome will transform how we conduct drug development, and lead to the development of Precision Microbiome Therapeutics.
Bill Cheliak, Ph.D.
Bill Cheliak, Ph.D. has over 25 years of business experience at the Executive and CEO level in a wide variety of life sciences. He has co-founded or assisted in development of companies in the fields of vaccines, human genetics, drug development, cancer, anti-infectives and pain. He has had extensive interactions with the pharmaceutical and financing industry. Bill has been involved in business development in with both private and publicly traded companies. He has executed numerous technology deals with Pharma, academic institutions and hospitals as well as helped securing dilutive and non-dilutive financing with many ventures. Bill currently serves on the Board of Directors of two publicly traded company on the TSX and served as Chair of the Government of Canada Network Centers of Excellence. He has a PhD in Genetics.
Daniel Figeys, Ph.D.
Co-founder & President
Daniel Figeys, Ph.D. is a Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He is a Distinguished Research Chair in Proteomics and Systems Biology and an International Professor in the Chinese Academy of Sciences. He was the founding Director of the Ottawa Institute of Systems Biology and directed the institute for 10 years. Prior to joining the University of Ottawa, Daniel was Senior Vice President Systems biology and Lead Profiling at MDS-Proteomics, a privately held company. Daniel obtained a B.Sc. and a M.Sc. in chemistry from the Université de Montréal. He obtained a Ph.D. in chemistry from the University of Alberta and did his postdoctoral studies at the University of Washington. His laboratory has published over 190 papers and has been cited over 15,000 times.
Alain Stintzi, Ph.D.
Co-founder & CSO
Alain Stintzi, Ph.D. is a professor with the Department of Biochemistry, Microbiology and Immunology, a member of the Ottawa Institute of Systems Biology, and Vice-Dean of Graduate and Postdoctoral Studies at the Faculty of Medicine, University of Ottawa. Dr. Stintzi obtained his Ph.D. in Molecular and Cellular Biology at the Louis-Pasteur University, France (1997). He was subsequently a Postdoctoral fellow at the Department of Chemistry, University of California at Berkeley. In 2000, he was appointed Assistant Professor at the Department of Veterinary Pathobiology, Oklahoma State University. Dr. Stintzi has considerable experience in systems biology approaches to study the role of the gut microbiota in infectious and chronic diseases. Dr. Stintzi has published over 63 articles and book chapters and has contributed to more than 150 scientific and educational conferences.
Shane Climie, Ph.D.
vp, BUSINESS DEVELOPMENT
Shane Climie, Ph.D. is a Principal with Popper and Company, which is focused on building life science organizations by meeting the needs of entrepreneurial, life science startups and the investors that support those early stage organizations. He is also President of Shane Climie & Associates which is focused on the provision of consulting services to life science companies. Dr. Climie is also Vice President of Business Development at MedBiome Inc. where he is responsible for corporate development, strategy and partnering. Dr. Climie also serves as Vice President of Corporate Development at Cyclica Inc. where he supports company growth by managing corporate relationships and strategic planning. Dr. Climie has more than 25 years of R&D and business development experience in the life sciences and pharmaceutical industry. He has led research teams involved in all aspects of drug discovery and technology development, and has designed, negotiated and managed many R&D collaborations. He has extensive experience in technology evaluation, technology development and strategic planning. Dr. Climie has been a Principal at Popper and Company for 13 years where he has provided interim executive management services to early-stage biotechnology companies in the areas of diagnostics and drug discovery / drug development as well as support in the areas of business management, marketing strategy and technology or opportunity assessment. Prior to his current appointments, Dr. Climie held several positions at Protana (formerly MDS Proteomics) including Senior Vice President of Science Strategy and Business Development, Senior Vice President of Research Collaborations, and Vice President of Proteomics and Business Development. Dr. Climie was also co-founder, Vice President and Chief Technology Officer of MDS Ocata and was a Visiting Research Scientist at the Samuel Lunenfeld Research Institute. Prior to that, Dr. Climie held several managerial positions at Allelix Biopharmaceuticals, Inc. including Principal Scientist. Dr. Climie completed postdoctoral work at the University of California at San Francisco and received a Ph.D. in Medical Biophysics from the University of Toronto.
David Mack, M.D. FRCPC
Professor, Department of Pediatrics, University of Ottawa
Director, CHEO Inflammatory Bowel Disease Centre
Division of Gastroenterology, Hepatology & Nutrition, Children’s Hospital of Eastern Ontario(CHEO)
Dr. Mack is currently a Professor with the Department of Pediatrics in the Faculty of Medicine, at the University of Ottawa; Director of the Children’s Hospital of Eastern Ontario (CHEO) Inflammatory Bowel Disease Centre He is the Pediatric Lead of the Clinical Affairs Committee of the Canadian Association of Gastroenterology and currently Deputy-Chair of the Canadian Children Inflammatory Bowel Disease Network. Dr. Mack obtained his medical degree from the University of Toronto in 1983. He was appointed to faculty at the University of Nebraska School of Medicine in the United States in 1991. Dr. Mack completed his Pediatric Residency training at CHEO, and Residency training and Pediatric Gastroenterology Fellowship at the Hospital for Sick Kids in Toronto. His research Interests include pediatric Inflammatory Bowel Disease and the intestinal microbiome in pediatric Crohn’s disease and ulcerative colitis.